EU Supplementary Protection Certificate Mechanism Needs To Go, Say Campaigners

A group of more than 30 NGOs has urged the European Commission to consider abolishing the system of granting supplementary protection certificates to pharmaceutical companies, saying it delays generic competition and affects the availability of affordable medicines. A UK-based patent attorney, however, says the assertions made by the NGOs are not supported by the evidence.

Brain
SPCs prolong monopolies of originator pharmaceutical companies, say campaigners • Source: Shutterstock

More from Legal & IP

More from Pink Sheet